Abstract
Inhaled corticosteroid (ICS) therapy plays a pivotal role in the long-term treatment of childhood asthma. The reduction of asthma symptoms and the improvement of quality of life (QOL) of the patients and their guardians are expected when ICS therapy in conformity with the guideline (JPGL2005) becomes familiar in primary care. The efficacy and safety of ICS therapy depends on the application of proper medication and on the continuous patient education.
